Revenues from mass cytometry instruments, consumables, and service increased 48 percent to $19.1 million from $12.9 million in Q4 2017.
The firms will cooperatively promote Indica's HALO image analysis tools with Fluidigm's Hyperion imaging mass cytometry platform and related products.
The approach allows researchers to profile the protein complexes present in a sample in much the same way they have the individual peptides and proteins.
The Swiss firm's ScaiVision software identifies disease-linked cells using AI, data visualization, and automation of hypothesis testing.
In 2018 Thermo Fisher posted $24.36 billion in revenues, up 16 percent from $20.92 billion in 2017 and beating the consensus analyst estimate of $24.08 billion.
The researchers presented new reagents and software for de novo peptide sequencing, an emerging technology with potential in proteomics and biopharma.
Under the agreement, MRM Proteomics has granted Biodesix rights to use its iMALDI mass spectrometry technologies to develop blood-based tests for lung cancer.
In initial testing, the approach distinguished between stage I cancer cases and healthy controls with 95 percent sensitivity and 100 percent specificity.
Driven by strong pharma sales, revenues increased to $715 million from $687 million in Q4 2017, besting the consensus analyst estimate of $703 million.
The subtypes — which were distinguished from one another using proteomic data — were associated with proliferation, immune response, metabolism, and invasion.
Among the updates provided at the conference on Wednesday, Luminex discussed development and plans for the Verigene II system, and GenMark touted its ePlex test portfolio.
The resource provides a look at protein localization patterns across the proteome as well as responses to events like alternative splicing and drug perturbation.
Cell Guidance Systems will use Expedeon's Lightning-Link Rapid Biotin reagent kit in the development of its TRIFic exosome immunoassay technology.
The partners will work to find novel proteins, including DNA endonucleases, to develop new gene editing therapies for cystic fibrosis and other diseases.
The firm is using collaborations to access the large, diverse cohorts it needs to support its goal of commercializing its SomaScan system as a clinical platform.
The team compiled these proteins in three panels that could help researchers better assess plasma sample quality in protein biomarker work.
The New York Department of Health-certified tests are based on proprietary algorithms licensed from Columbia University, which offers them in the US.
The partners will leverage Singapore’s clinical network to collect a variety of 'omics data from consenting individuals and store the data for local researchers to investigate.
The company is currently using the model, named EDGE, in its own personalized cancer vaccine work and in collaboration with outside immunotherapy developers.
The companies will use Somalogic's SomaScan proteomic platform to measure levels of as many as 5,000 proteins in up to 40,000 of DeCode's patient samples.
NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.
According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.
A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.
In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.